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Abstract
Aquaporins (AQPs) have previously been associated with increased expression in solid tumors. However, its expression in
hematologic malignancies including CML has not been described yet. Here, we report the expression of AQP5 in CML cells
by RT-PCR and immunohistochemistry. While normal bone marrow biopsy samples (n=5) showed no expression of AQP5,
32% of CML patient samples (n=41) demonstrated AQP5 expression. In addition, AQP5 expression level increased with the
emergence of imatinib mesylate resistance in paired samples (p=0.047). We have found that the overexpression of AQP5 in
K562 cells resulted in increased cell proliferation. In addition, small interfering RNA (siRNA) targeting AQP5 reduced the cell
proliferation rate in both K562 and LAMA84 CML cells. Moreover, by immunoblotting and flow cytometry, we show that
phosphorylation of BCR-ABL1 is increased in AQP5-overexpressing CML cells and decreased in AQP5 siRNA-treated CML
cells. Interestingly, caspase9 activity increased in AQP5 siRNA-treated cells. Finally, FISH showed no evidence of AQP5 gene
amplification in CML from bone marrow. In summary, we report for the first time that AQP5 is overexpressed in CML cells
and plays a role in promoting cell proliferation and inhibiting apoptosis. Furthermore, our findings may provide the basis for
a novel CML therapy targeting AQP5.
Citation: Chae YK, Kang SK, Kim MS, Woo J, Lee J, et al. (2008) Human AQP5 Plays a Role in the Progression of Chronic Myelogenous Leukemia (CML). PLoS
ONE 3(7): e2594. doi:10.1371/journal.pone.0002594
Editor: Mikhail V. Blagosklonny, Ordway Research Institute, United States of America
Received March 26, 2008; Accepted April 23, 2008; Published July 9, 2008
Copyright:  2008 Chae et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by the SPORE grant (P50 CA96784-01), Cancer Research Grant from Pyung-Ya Foundation (C.M.) and the Basic Research
Program Grant of the Korea Science & Engineering Foundation (R21-2007-000-10041-0, 2007) (D.K.).
Competing Interests: David Sidransky is a paid consultant to Cangen Biotechnologies, Inc.
* E-mail: cmoon5@jhmi.edu
Introduction
Aquaporins (AQPs) are water channel proteins that facilitate
transcellular water movements [1,2]. Each of the ten known
human AQPs has a unique expression pattern [1]. For example,
AQP type 5 (AQP5) is found in various epitheliums including
lacrimal [3], salivary [4], and airway submucosal glands [5],
pancreatic epithelium [6], and type I pneumocytes [7]. Although
the role of AQPs in human pathology has been explored
extensively, only recently has its role in cancer become an area
of interest. The ectopic expression of human AQPs has been
reported to be frequently associated with various cancers. For
instance, AQP1 is expressed in brain [8], colon [9], and pancreatic
cancers [6] and the microvessels in multiple myeloma [10], AQP3
in renal cell carcinoma [11] and AQP5 in colon [9], pancreatic
[6], and ovarian cancers [12]. We have also previously reported
that AQP5 expression is associated with an early stage of colorectal
cancer development
9. Interestingly, the expression of human
AQP1, AQP3, and AQP5 was detected in tumor-infiltrating
lymphocytes surrounding bronchogenic cancer of lung [13].
AQP1, AQP3, and AQP5 are also simultaneously induced during
lymphocyte activation [13].
In addition to the above expression studies, recent molecular
and biochemical studies have alluded to the role of AQPs in
human carcinogenesis. AQP1 is shown to play a role both in
angiogenesis [14] and cell cycle control [9,15], assisting cancer
development. Our group has reported that the expression of wild-
type AQP5 (AQP5) in a NIH3T3 mouse fibroblast cell line
induced many phenotypic changes characteristic of transformation
in vitro and in vivo by triggering signaling pathways activated
through Ras, which is induced by phosphorylation of the PKA
consensus site of AQP5 [16,17]. Interestingly, athymic mice
injected with NIH3T3 cells stably transfected with AQP5
exhibited a robust tumor formation [17]. Most recently, we have
demonstrated that AQP5 promotes cell proliferation and that its
overexpression is related with liver metastasis; we have also found
molecular pathways based on the Ras/ERK/Rb signaling
pathway as a mechanism to promote cell proliferation in colon
cancer cells [18]. Furthermore, we have observed that AQP5
triggers invasion and epithelial-mesenchymal transition in BEAS-
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expression showed a significant association with earlier disease
progression in NSCLC patients of more than 400 [19].
To build on our findings from the colon and lung cancer
models, in this report, we have studied the AQP5 expression
pattern and its role in human chronic myelogenous leukemia
(CML). To date, no study has demonstrated the expression of
AQP5 in hematologic malignancies. Here, we show that AQP5 is
expressed in CML cells and that the expression level of AQP5 may
be associated with the progression of CML. Furthermore, we
hypothesize that, like in the solid tumors mentioned above, AQP5
may trigger cell proliferation in leukemic cells.
Materials and Methods
Cell lines and drugs
The human CML cancer cell lines EM-2 and LAMA-84 were
purchased from DSMZ (Germany), K562 from ATCC (USA).
Human monoblastic leukemia cell line U937 was also purchased
from ATCC (USA). All cell lines were cultured in RPMI medium
(Invitrogen) with 10% fetal bovine serum (Gibco) and antibiotics.
All the cell lines were cultured at 37uC in a humidified
environment containing 5% CO2. Imatinib mesylate was a kind
gift from Novartis (Basel, Switzerland).
Patient bone marrow samples
Human bone marrow biopsy and aspirate samples were
obtained from randomly selected patents from St. Mary Hospital
and Seoul National University Hospital (Seoul, Korea). 41 biopsy
samples were from CML patients and 5 from normal bone
marrow transplant donors. 41 aspirate samples were from the
former and 3 from the latter. At the time of the blood donation,
written informed consent to the participation in the research
campaign was obtained. This study was approved by the
institutional review boards of St. Mary Hospital and Seoul
National University Hospital.
RT-PCR analysis of AQP5 mRNA expression
We isolated RNA using Trizol (Invitrogen) and reverse-
transcribed total RNA (8 mg) with Moloney Murine Leukemia
Virus (M-MLV) reverse transcriptase (Invitrogen) and one
hundredth of the DNA was used as a template for polymerase
chain reaction (PCR). Reverse transcriptase polymerase chain
reaction (RT-PCR) was performed at 30 cycles: 95uC for 1 min,
55uC for 1 min, and 72uC for 1 min. The expression levels of
AQP5 were measured semiquantitatively in CML cell lines and
normal bone marrow cells. (AQP5, sense: AAGAAGGAGGTG-
TGTTCAGTTGCCTTCTTCA and antisense: GTGTGCC-
GTCAGCTCGATGGTCTTCTTCCG; GAPDH, sense: GCC-
TCAAGATCAGCAAT and antisense: AGGTCCACCACTGA-
CACGTT) For quantitative measurement of AQP5 mRNA in
lung and breast cancer tissues, leukemia bone marrow sample, and
peripheral blood (all from the tissue bank), QuantiGeneH 2.0 RNA
Quantification System using branched DNA technology (Sigma-
Aldrich) was used according to manufacturer’s instruction. For the
calculation of the relative expression level of AQP5, the ratio
between AQP5 mRNA and GAPDH mRNA was used.
Immunohistochemistry
The expression of AQP5 in normal bone marrow (n=5) and
CML (n=41) was examined by immunohistochemistry. Bronchial
carcinoma tissues from The Catholic University of Korea tissue
bank were analyzed simultaneously as positive control. Paraffin-
embedded tissue sections, sliced in 4 mm thickness, were
deparaffinized in xylene and were rehydrated through graded
alcohol, and followed by endogenous peroxidase blocking with
0.3% hydrogen peroxide for 10 min. Antigen retrieval was
performed using pressure cooker at 121uC, 10 Lb in sodium
citrate buffer (pH 6.0) for 3 min. They were incubated with
10 mg/ml anti-AQP5 antibody (Calbiochem, EMD Chemicals
Inc., Darmstadt, Germany) overnight at 4uC. After washing, the
secondary antibody was applied and incubated for 30 min at room
temperature. Finally, the slides were covered with the mixed
solution of DAB and HRP substrate buffer to develop the color
and washed with deionized water, and followed by hematoxylin
counterstaining. The visualization procedure was performed using
the DAKO REALTM EnVisionTM Detection System (DAKO,
Glostrup, Denmark).
Scoring of Immunohistochemistry
Immunostaining was graded semi-quantitatively considering
staining intensity by two pathologists (M.K. and G.P.) blinded to
the clinicopathologic variables. The staining intensity was
arbitrarily scored on a scale of three grades: negative, trace, and
positive (Figure 1A).
Construction of hAQP5 cDNA expression construct
Human AQP5 cDNA was amplified by polymerase-chain
reaction (PCR) using primers and then inserted into the EcoR I
and XhoI sites of pcDNA 3.1(+). Cloned genes were confirmed by
restriction analysis and by DNA sequencing of both strands.
Expression constructs were transfected into K562 CML cell lines
with Nucleofactor (Amaxa) according to manufacturer’s recom-
mendations. Transfection efficiency tested with enhanced green
fluorescence proteins (Amaxa) was approximately 60–70 percent
(Figure S1). Transfectants were selected with 600 mg/mL G418
for K562 cell line.
Immunoblotting
Lysates from cultured cells and tissues were prepared in ice-cold
NP-40 lysis buffer (10 mM Tris-Cl (pH 7.4), 137 mM NaCl, 10%
glycerol and 0.1% Nonidet P-40) containing an inhibitor cocktail
of 10 mM b-glycerol phosphate, 1 mM phenylmethylsulfonyl
fluoride, 10 mM NaF, 10 mM Na orthovanadate, 4.5 U/ml
aprotinin (Sigma), and 1 mg/ml leupeptin (Sigma). Crude protein
lysates (25 mg) were separated by 4–12% SDS-PAGE (Invitrogen),
transferred to nitrocellulose membranes (BIORAD), and blocked
for 1 hour with 5% nonfat dry milk in Tris-buffered saline with
0.05% Tween-20. The following commercial antibodies were used
for Western blot analysis: anti-AQP5 (1:200; Alpha Diagnostic),
anti-phospho-Bcr (1:1000; Cell Signal), anti-c-Abl (1:1000; Cell
Signal), anti-phospho-Akt (1:1000; Cell Signal), and anti-beta actin
antibody (1:5000; Sigma). Appropriate anti-rabbit and anti-mouse
horseradish peroxidase-conjugated secondary antibodies (1:5000;
Amersham) were used. Immunoreactive bands were detected by
enhanced chemiluminescence (Pierce).
Small interfering RNA (siRNA) treatment
One pool containing four siRNAs targeting human AQP5 and a
second pool containing four nonspecific siRNAs, as a negative
control, were designed and synthesized to have the least off-target
effects using SMART-pooled technology (Dharmacon). All siRNA
sequences are described in the Supplementary Methods S1. Cells
were transfected with 100 nM of siRNAs in Opti-MEM I reduced
serum medium (Invitrogen) using RNAi Max transfection reagent
(Invitrogen) according to the manufacturer’s instruction and
cultured at 37uC in a 5% CO2 atmosphere. The medium was
AQP5 in CML
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supplemented with 10% FBS. The growth of each cell line was
measured by MTT assay three days after treatment. Measure-
ments were made in triplicate for each of the cell lines and the
experiments were repeated three times.
Cell proliferation assay
WST-1 assay were used to evaluate cell proliferation rate (Cell
Counting Kit-8, Dojindo) in both cDNA and siRNA transfection
experiements. ATP concentration was measured (CellTiter-GloH
Luminescent Cell Viability Assay, Promega) to assess cell viability
in siRNA experiments. For cDNA transfection experiements, cells
were grown in six-well plates at a density of 2.5610
5 cells per well
for 4 days. For siRNA experiments, cells were cultured in six-well
plates at a density of 5610
5 cells per well for 3 days.
Measurements were made in triplicate for each of the cell lines
and the experiments were repeated three times
Apoptosis assay
Caspase 3, 8, and 9 concentrations were measured (Caspase-
GloH Luminescent Assay, Promega) to assess apoptosis activity in
siRNA experiments. Cells were grown in six-well plates at a
Figure 1. AQP5 expression assay. (A) RT-PCR analysis shows that AQP5 is expressed in human leukemic cell lines (1, K562; 2, U937; 3, EM-2; 4,
LAMA-84). GAPDH is loaded as control. (B) The relative expression levels of AQP5, the ratio between AQP5 mRNA and GAPDH mRNA, from
QuantiGene RNA Quantification System using branched DNA technology (Sigma-Aldrich) are compared between human lung cancer and breast
cancer tissues, CML cells (blood cancer), and normal peripheral blood lymphocytes. While the first three showed expression of AQP5, AQP5 was rarely
expressed in normal lymphocytes. (C) Immunohistochemical localization of AQP5 is shown in normal bone marrow (negative control) and lung
adenocarcinoma (positive control). AQP5 immunostaining is negative for normal bone marrow (A, 6400), whereas AQP5 is localized in both apical
and basal membrane of malignant lung tumor cells (B, 6400). (D) Photomicrographs of AQP5 immunostaining in CML bone marrow samples are
shown with the examples of negative, trace(6), positive (+) immunoreactivity (6400). A; negative, B; trace(6), some megakaryocytes (open arrow)
showing weak cytoplasmic staining, C; positive (+), granulocytes (arrow) showing strong staining and blasts (inlet) showing weak staining.
doi:10.1371/journal.pone.0002594.g001
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5 cells per well for 3 days. Light microscopy and
Trypsin Blue staining was used to describe cells undergoing
apoptosis. Measurements were made in triplicate for each of the
cell lines and the experiments were repeated three times.
Flow cytometry analysis
Flow cytometry was performed to evaluate BCR-ABL1
phosphorylation in AQP5/control siRNA and imatinib-treated
(positive control) LAMA-84 CML cell lines. First, cells were
washed in cold PBS twice, fixed with 2% formaldehyde for 10 min
at 37uC, permeabilzed with ice-cold 90% methanol for 30 min,
and aliquot 5610
5 cells into each assay tube. Then, cells were
washed and resuspended with incubation buffer (0.5% bovine
serum albumin in PBS) and incubated for 10 min. Rabbit anti-
phospho-Bcr antibody (1:50; Cell Signal) was added to the tube for
1 hr incubation. After washing and resuspension with incubation
buffer, FITC-conjugated donkey anti-rabbit antibody (Jackson
Immunoresearch) was applied for 30 min incubation. Finally, cells
were rinsed with incubation buffer and resupended in 0.5 ml PBS.
Stained cells were analyzed on a FACS Caliber (Becton Dickinson,
San Jose, CA) within 30 minutes, and FACS data were analyzed
using Cell Quest software (Becton Dickinson).
Cytogenetic response analysis
A conventional metaphase karyotyping was performed with each
bone marrow examination. Bone marrow aspirate was introduced
into the culture medium, and harvested at 48 hours. The harvest and
slide preparations were completed according to standard methods
and G-banded metaphases were analyzed. BCR/ABL amplification
was alsoconfirmed using interphase fluorescence in situ hybridization
(FISH) using LSI BCR/ABL dual color, dual fusion translocation
probe (Vysis Inc., Des Plaines, IL). Furthermore, bcr/abl mutation
screening was performed using allele specific oligonucleotide
polymerase chain reaction (ASO-PCR) methods previouslydescribed
[20]. Bcr/abl mutations that are reported to be associated with
imatinib mesylate resistance have all been screened [21].
Detection of AQP5 gene amplification
FISH of the bone marrow cells was performed in 41 CML patients
and 3 control cases. The probe for AQP5 was derived from Homo
sapiens 12 BAC RP11-469H8 containing the whole AQP5 gene
(GenBank Accession no. AC025154), and labeled with Cy3 (Macro-
gen, Seoul, Korea). Two genomic DNA clones franking 12p13.33
region labeled with FITC were used as control probes (Macrogen).
FISH was performed according to the manufacturer’s instructions.
Statistical Analysis
Fisher-Freeman-Halton exact test and Student’s t-test were used
to assess the association between AQP5 expression and demo-
graphic and clinicopathological variables. In addition, Wilcoxon
Signed-Rank test was used to compare the AQP5 expression level
before and after the emergence of imatinib mesylate resistance.
Differences found between samples in cell proliferation assay, cell
counting, and apoptosis assay were examined by Student’s t-test.
All p-values were derived from two-sided test and were considered
to be statistically significant if less than 0.05. All statistical analyses
were performed using STATA Statistical Software, 9.0 (Stata
Corporation, College Station, TX, USA).
Results
AQP5 is expressed in human CML cells
First, we studied the expression profile of AQP5 in leukemic cell
lines as well as CML primary cells. With RT-PCR analysis, K562,
EM-2, and LAMA-84 human CML cell lines and U937 human
monoblastic leukemia cell line showed a clear expression of AQP5
(Figure 1A). This finding was confirmed with mRNA quantifica-
tion in primary CML cells (Figure 1B). Standardized mRNA levels
of AQP5 (AQP5 mRNA/GAPDH mRNA) in lung and breast
cancer tissue (positive control) and normal peripheral blood
lymphocytes (negative control) were compared to that of CML
cells for comparison (Figure 1B). The expression level of AQP5 in
CML cells was lower than that of lung and breast cancer tissues.
However, AQP5 expression was rarely detected in normal
peripheral blood lymphocytes. Then, the protein expression level
of AQP5 was examined with bone marrow biopsy samples by
immunohistochemisty (Table 1, Table S1). While all the normal
bone marrow biopsy samples (n=5) showed no expression of
AQP5 (Figure 1C), 13 out of 41 (32%) CML patient samples
demonstrated AQP5 expression (Figure 1D). Among those with
expression, 10 samples were clearly positive, while 3 samples were
trace (Figure 1D). In positive cases of CML, megakaryocytes and
myeloblasts showed weak cytoplasmic staining, whereas granul-
cytes exhibited markedly strong staining (Figure 1D). As expected,
the staining intensity of AQP5 in CML cells was weaker than that
of lung tumor cells (positive control), consistent with the mRNA
findings (Figure 1C) and our recent observations in NSCLC
[17,19]. For bone marrow cells, mRNA level of AQP5 could not
be examined owing to the insufficient amount of the samples.
However, a direct association between expression level detected
from RT-PCR analysis and immunohistochemistry was found in
our preliminary analysis. Therefore, it is probable that RT-PCR
analysis would demonstrate similar results.
Table 1. AQP5 expression and demographic and
clinopathologic characteristics of the CML patients.
Patient characteristics AQP5 expression p value{
2 +
Sex, Female 53.6% (15/28) 53.8% (7/13) 0.744
Age, mean (SD) 41.6 (13.4) 44.3 (17.7) 0.596
bcr-abl amplification 25.0% (7/28) 15.4% (2/13) 0.692
bcr-abl mutation 25.0% (7/28) 30.8% (4/13) 0.719
Secondary chromosomal changes* 35.7% (10/28) 46.2% (6/13) 0.732
Phase at diagnosis 0.003
Chronic 75.0% (21/28) 38.5% (5/13)
Accelerated 10.7% (3/28) 38.5% (5/13)
Blast crisis 3.6% (1/28) 7.7% (1/13)
Imatinib mesylate resistance 50.0% (14/28) 61.5% (8/13) 0.524
Phase at resistance 0.004
Chronic 14.3% (2/14) 50.0% (4/8)
Accelerated 0% (0/14) 25.0% (2/8)
Blast crisis 71.4% (10/14) 25.0% (2/8)
Days to resistance{, mean (SD) 559 (351) 636 (320) 0.437
*Secondary chromosomal change denotes abnormal changes detected from
conventional karyotyping test other than bcr-abl amplification; t(9,22).
{Time to resistance represents the interval between the days imatinib mesylate
was started to the day resistance to the drug emerged.
{P values were derived from Student’s t-test (age and days to resistance) and
Fisher-Freeman-Halton exact (other variables).
SD denotes standard deviation.
doi:10.1371/journal.pone.0002594.t001
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aggressiveness in CML progression
We then decided to see whether AQP5 expression in CML cells
bears any clinical significance. Thus, we gathered demographic
and clinopathologic information of the CML patients (Table 1,
Table S1) and analyzed their association with AQP5 expression
level. The expression level of AQP5 was associated with CML
phase at the time of diagnosis and of resistance (p=0.03, p=0.04,
respectively). Interestingly, AQP5 expression level was relatively
higher among CML patients diagnosed at accelerated, or blast
crisis, phase than those diagnosed at chronic phase (Table 1). On
the other hand, AQP5 expression level was relatively higher
among CML patients who gained imatinib mesylate resistance at
chronic phase than those who gained resistance at accelerated, or
blast crisis, phase. These findings may allude to the notion that
AQP5 expression is linked with more aggressive behavior in CML
progression.
No statistically significant relationship was found between the
expression level of AQP5 and patient’s age, sex, the time interval
from diagnosis to resistance, and the time interval from resistance
to sampling. In general, there was no statistically significant
relationship between AQP5 expression level and the existence of
imatinib mesylate resistance in the bone marrow samples (n=41,
p=0.524). However, when AQP5 expression levels were com-
pared between the paired bone marrow samples drawn before and
after the emergence of imatinib mesylate resistance in the same
CML patients (n=9), a statistically significant difference was found
(p=0.047) (Table 2). Intriguingly, AQP5 expression increased
with the appearance of imatinib mesylate resistance. This finding
suggests that AQP5 may play a role in the process of developing
imatinib mesylate resistance in CML. Accordingly, we have
further examined whether AQP5 expression in CML cells is linked
with bcr-abl amplification, or mutation, or secondary chromo-
somal changes other than t(9,22) in imatinib mesylate resistant
CML cases. In our 41 CML bone marrow samples, although a
gain of bcr-abl amplification, mutation, and secondary chromo-
somal changes were found to be associated with the development
of imatinib mesylate resistance (p=0.002, p,0.001, p=0.001,
respectively), none of them showed a statistically significant
correlation with AQP5 expression (Table S1). In paired bone
marrow samples drawn before and after the emergence of imatinib
mesylate resistance, like AQP5 expression, a gain of bcr-abl
mutation revealed an independent association with the develop-
ment of drug resistance (p=0.025) (Table 2). Thus, AQP5
expression in CML does not seem to be associated with the major
mechanisms of imatinib mesylate resistance including bcr-abl
amplification and mutation [21].
AQP5 expression stimulates CML cell proliferation
Based on our results from the expression assay and the clinical
correlation analyses, we chose to explore the molecular mecha-
nism behind the expression of AQP5 in CML cells. First, we
decided to investigate whether AQP5 promotes cell proliferation
in CML cells by measuring cell proliferation rates between K562
CML cell lines stably transfected with AQP5 and vector pcDNA.
Notably, the former showed a significantly higher proliferation
rate than the latter (p,0.01) (Figure 2). Also, similar results were
replicated in other CML cell lines such as EM-2 and LAMA-84
(data not shown).
AQP5 activates cell signaling pathway molecules in CML
cells
Then, we checked whether AQP5 expression triggers the
activation of cell signaling molecules involved in CML cell
proliferation. Of note, K562 CML cells stably overexpressing
AQP5 demonstrated an increase in BCR (Tyr177) phosphoryla-
tion as well as Akt (Thr308) phosphorylation (Figure 3). Since
BCR (BCR-ABL1) and Akt are cell signaling molecules critical for
the proliferation of CML cells [22], our finding provides a
molecular basis for the involvement of AQP5 in the progression of
CML.
Ablation of AQP5 induces not only decreased cell
proliferation but also enhanced apoptosis in CML cells
We have decided to validate our findings from AQP5
overexpression study by ablating AQP5 expression with a small
inferring RNA (siRNA). As expected, LAMA-84 CML cells
treated with AQP5 siRNA showed a marked decrease in cell
proliferation compared with cells treated with control siRNA
(p,0.01) (Figure 4A). This was further confirmed by examining
ATP concentration reflecting viable cell numbers between the two
cell lines (Figure 4B); cells treated with control siRNA demon-
strated higher number of viable cells than cells treated with AQP5
Table 2. AQP5 expression level and CML Patient information.
patient AQP5 expression bcr-abl amplification bcr-abl mutation secondary chromosomal change*
Pre R Post R Pre R Post R Pre R Post R Pre R Post R
A 22 2+ 2 + 2 +
B 2 ++ 22 2+ 2 +
C ++ ++ 22 2++ +
D 22 22 22 + 2
E 2 + 22 22 22
F 2 + 22 2+ 2 +
G 22 22 2+ 22
H 22 22 22 2+
I ++ + 22 22 22
*Secondary chromosomal change denotes abnormal changes detected from conventional karyotyping test other than bcr-abl amplification; t(9,22).
preR and postR denote AQP5 expression level, or the existence of bcr-abl amplification, mutation, or secondary chromosomal change before and after the emergence of
imatinib mesylate resistance, respectively.
doi:10.1371/journal.pone.0002594.t002
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cell line, since it showed the highest siRNA transfection efficiency
among CML cell lines in our preliminary analysis. The ability of
the pooled siRNA to silence AQP5 expression was validated with
RT-PCR analysis. Similar results were also replicated with K562
cell line (data not shown).
In addition, deactivation of cell signaling molecules was also
demonstrated in K562 cells treated with AQP5 siRNA compared
with cells treated with control siRNA (Figure 3); the former
showed decreased phosphorylation of BCR (Tyr177) and Akt
(Thr308) than the latter. We also validated this finding with
LAMA-84 cell line using flow cytometry analysis (Figure 5).
Imatinib mesylate treatment was used as a positive control in terms
of deactivating BCR-ABL1 tyrosine kinase. As expected, cells
transfected with AQP5 siRNA demonstrated decreased phosphor-
ylation of BCR (Tyr177), reflecting deactivation of BCR-ABL1,
compared with cells transfected with control siRNA (Figure 5A,
5C). However, cells treated with imatinib mesylate showed a
stronger inhibition of BCR-ABL1 than cells treated with AQP5
siRNA (Figure 5A, 5B). These findings combined with the
expression study results corroborate our hypothesis that AQP5
expression promotes cell proliferation in CML.
To our surprise, we came across a noteworthy finding that
LAMA-84 CML cells transfected with AQP5 siRNA exhibited a
significantly higher caspase 9 activity than cells transfected with
control siRNA (p,0.01) (Figure 4C). Although not statistically
significant, similar results were also shown for caspase 3,
downstream pathway molecule of caspase 9 (data not shown).
Furthermore, light microscopy and Trypsin Blue staining
confirmed the differences in the number of cells undergoing
apoptosis; caspase 8 activity showed no difference between two cell
lines (data not shown). These findings indicate that AQP5
expression may play a role in inhibiting apoptosis in CML cells,
possibly through the caspase 9 pathway.
AQP5 expression in CML cells is not associated with
genomic amplification of AQP5
Finally, to elucidate the molecular mechanisms underlying
AQP5 expression in CML cells, we investigated the presence of
genomic amplification through fluorescence in situ (FISH) analysis
using an AQP5 gene probe. Out of 41 cases of bone marrow
aspirate samples of CML patient, no clear pattern of genomic
amplification was detected (Figure S2), suggesting that the
expression of AQP5 could be a secondary molecular event.
Discussion
Previous expression studies of AQP5 in human tissues, both
normal and malignant, have been only in epithelial tissues and
carcinomas. For instance, lung epithelium is a well known site of
Figure 2. Cell proliferation assay in K562 CML cell line stably expressing AQP5. Cell proliferation was measured with cell counting kit
between AQP5 wild-type (WT) and pcDNA vector transfected K562 stable cell lines. The former showed significantly higher proliferation rate than the
latter (p,0.01).
doi:10.1371/journal.pone.0002594.g002
Figure 3. Western blotting analysis in K562 CML cell lines
transfected with AQP5 pcDNA and AQP5 siRNA. Western blotting
analysis was performed in AQP5 WT versus vector (V) pcDNA
transfected K562 stable cell lines and pooled AQP5 siRNA versus
pooled control siRNA transfected K562 cell lines. While AQP5
transfected cell line displayed increased BCR (Tyr177) and Akt
(Thr308) phosphorylation, AQP5 siRNA transfected cell line showed
the opposite. siC, control siRNA treated; siA, AQP5 siRNA treated, c-ABL,
and tubulin were loaded as controls.
doi:10.1371/journal.pone.0002594.g003
AQP5 in CML
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be higher in non small cell lung cancer than in normal lung tissue
[22]. Of interest, it has been reported that aspirates of bone
marrow cells, fresh or cultured, can express AQP5, typically
expressed in the type I pneumocyte [23], and that bone morrow
derived cells can be precursors of differentiated parenchymal cells
of the lung [23,24]. Additionally, our group has previously shown
that human lymphocytes, when activated, can express AQP5 [13].
Based on these interesting observations and our findings from
human leukemic cell lines (Figure 1A), we have decided to study
the expression profile of AQP5 in human bone marrow, both
normal and malignant. Among 41 bone marrow biopsy samples
from CML patients, 32% exhibited AQP5 expression (Figure 1D).
However, normal bone marrow samples (n=5) showed no
expression of AQP5 (Figure 1C). This expression profile in
CML is comparable to that in solid tumors; AQP5 is expressed in
35% (144/408) of non-small-cell lung cancer [19], and similar
observations were also found in breast cancer (manuscript in
preparation). However, the relative mRNA expression level of
AQP5 in CML cells is found to be lower than that of lung and
breast cancer (Figure 1B). Interestingly, unlike carcinoma cells
where AQP5 shows membranous expression (Figure 1C), in the
bone marrows of CML patients, megakaryocytes, myeloblasts, and
granulocytes demonstrated cytoplasmic expression of AQP5
(Figure 1D). Thus, our findings, for the first time, describe the
unique expression pattern of AQP5 in the human bone marrow of
CML cases.
More interestingly, we found evidence that AQP5 may be
associated with the progression of CML. This finding is also
comparable to our previous findings that AQP5 expression
correlates with clinical outcomes in solid tumors, such as lung
metastasis in colon cancer [18], earlier disease progression in lung
cancer [19], and worse survival in breast cancer (manuscript in
preparation). CML patients diagnosed at accelerated or blast crisis
phase showed significantly higher level of AQP5 expression than
those diagnosed at chronic phase, while CML patients who gained
imatinib mesylate resistance at chronic phase exhibited signifi-
cantly higher level of AQP5 expression than those who gained
resistance at accelerated or blast crisis phase (p=0.03, p=0.04,
respectively). Furthermore, with paired sample analysis in the
Figure 4. AQP5 small interfering RNA experiment in LAMA-84 CML cell line. (A) Cell counting, (B) ATP concentration and (C) Caspase 9
assay was done (B, C on the 2nd day of transfection) in pooled AQP5 siRNA and pooled control siRNA transfected LAMA-84 cell lines. While AQP5
siRNA treated cell line demonstrated a notably decreased proliferation and cell viability (ATP concentration), it showed a markedly increased caspase
9 activity compared with control siRNA treated cell line (all p values,0.01).
doi:10.1371/journal.pone.0002594.g004
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appearance of imatinib mesylate resistance (p=0.047). Based on
these observations, we suspect that AQP5 may be conferring a
growth advantage in the process of CML progression. Further-
more, from our association study with the cytogenetic response
analysis (Table 2), we surmise that AQP5 may play a role in
developing imatinib mesylate resistance, irrespective of other
known major resistance mechanisms such as bcr-abl mutation or
amplification [21]. Further experiments are planned to examine
whether AQP5 ablation in combination with imatinib mesylate
treatment increases the susceptibility of the latter in imatinib
mesylate resistant CML cells.
Of late, the molecular mechanism underlying the observed
association between AQPs and human cancers has become the
focus of our research. We have previously demonstrated the
oncogenic property of AQP1 in NIH3T3 mouse fibroblast cell
line
23 and that of AQP5 in the same cell line [17]. Recently, we
have found that AQP5 expression in NIH3T3 cell line induces cell
proliferation through the activation of Ras, suggesting an
association between AQP5 and the Ras signal transduction
pathway [16,17]. In addition, we have reported that AQP5
triggers Ras/ERK/Rb pathway in HCT116 colon cancer cell line,
thereby promoting cell proliferation [18]. Furthermore, we have
observed that AQP5 activates c-Src, and, thus, triggers cell
invasion and epithelial-mesenchymal transition (EMT) in BEAS-
2B human bronchial epithelial cell line [19]. However, these
finding were all based on solid tumors and the role of AQPs in the
development of hematological malignancies are largely unknown.
Thus, in this study, we have pursued the role of AQP5 in CML as
a first model to study the role of AQPs in blood cancer.
We report, for the first time, that AQP5 promotes cell
proliferation in CML cell lines possibly through the activation of
BCR-ABL1 and Akt. We have also found that AQP5 may prolong
cell survival by inhibiting apoptosis via caspase 9 pathway. We
believe that these findings may shed light in discovering novel
molecular targets for CML treatment, where drug resistance has
become a huge obstacle for oncologists [21]. However, there needs
to be further investigation into several other candidate cell
signaling pathways important in CML progression that may be
affected by AQP5. Our next plan is to examine changes in the
signal transduction molecules related with the BCR-ABL1
pathway such as CrkL, Ras, Jak2, Stat5, and c-Myc [26] as well
as molecules that are not linked with BCR-ABL1 pathway
including Lyn [30] in both AQP5-overexpressing and AQP5-
silenced CML cell lines. Also, we plan to delve into the details of
the apoptosis pathways including Bcl-2, Bax, Bad, and Fas [27].
Ultimately, our findings including proliferation assay and
molecular expression assays await further validation with primary
CML cells.
One question that may arise is the identification of the adaptor
molecule that directly interacts with AQP5 to exert its alleged
effects in CML. One possibility is for AQP5 to interact with and,
thus, activate Lyn in CML cells. With protein microarray and
GST pull-down assay, we have reported that AQP5 binds to Lyn
[19], the activation of which has been found to be one of the
mechanisms of imatinib mesylate resistance [28]. Similar to our
findings, Lyn ablation led to enhanced apoptosis of CML cells,
even in primary cells resistant to imatinib mesylate therapy [29].
Although the pathway of Lyn activation seems to be independent
of BCR-ABL1 [28], it would be worthwhile to explore the possible
interaction between Lyn and AQP5 in CML cells and see how
AQP5 ablation affects the growth of imatinib mesylate-resistant
primary CML cells. In addition, our recent studies suggest that
Grb2 (manuscript submitted) and c-Src [19], both of which
showed in vitro and in vivo binding with AQP5, could be some of the
candidate adaptor molecules which interact with AQP5 in CML
cells. Thus, we plan on performing binding assays with the above
candidate molecules in CML cell lines and primary CML cells.
Lastly, the possibility that AQP5 can function as a kinase itself
should not be ignored.
Another question that remains is why AQP5 is overexpressed in
certain CML cells. In our FISH analysis (n=41), we found no
genomic amplification of AQP5 (Figure S2), indicating that AQP5
expression may be a secondary phenomenon. This is similar to our
finding with AQP1 [25] and AQP5 [19] in lung, where no
evidence for genomic amplification was detected. Currently, we
are investigating the presence of AQP5 mutation with the CML
samples, especially with the paired samples drawn before and after
the emergence of imatinib mesylate resistance in the same CML
patients. Our previous efforts to identify a promoter element
responsible for the induced expression of AQP5 in several tumor
cell lines suggested the existence of several potential cis-acting
Figure 5. Flow cytometry analysis in AQP5 siRNA treated
LAMA-84 CML cell line. Flow cytometry analysis was performed in
pooled control siRNA (negative control) (A), imatinib mesylate of
500 nM concentration (positive control) (B) and pooled AQP5 siRNA (C)
transfected LAMA-84 cell lines. Cells treated with control siRNA showed
a significantly decreased phosphorylation in BCR (Tyr177) than cells
treated with AQP5 siRNA. Cells treated with imatinib mesylate showed
better inhibition of BCR phosphorylation than cells treated with AQP5
siRNA.
doi:10.1371/journal.pone.0002594.g005
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analysis of the AQP5 promoter region suggested that promoter
demethylation may play a role in the expression of AQP5 in head
and neck and lung cancer cell lines (manuscript in preparation).
These results, however, are still preliminary and warrant further
validation.
In conclusion, this is the first report, to our knowledge, to show
that human AQP5 is expressed in CML cells with a potential role
in cancer progression and plays a role not only in proliferation, but
also in survival of CML cells. Moreover, they also provide a
potential basis for designing a novel CML therapy targeting
AQP5. Further expression profile studies in other hematologic
malignancies such as acute leukemia and lymphoma are planned.
Comprehensive functional studies to verify the novel oncogenic
and anti-apoptotic properties of AQP5 in blood cancer are also
warranted.
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